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Available online 14 December 2016Transcriptional dysregulation is observable in multiple animal and cell models of Huntington's disease, as well as
in human blood and post-mortem caudate. This contributes to HD pathogenesis, although the exact mechanism
by which this occurs is unknown. We therefore utilised a dynamic model in order to determine the differential
effect of growth factor stimulation on gene expression, to highlight potential alterations in kinase signalling path-
ways that may be in part responsible for the transcriptional dysregulation observed in HD, and whichmay reveal
new therapeutic targets. We demonstrate that cells expressing mutant huntingtin have a dysregulated transcrip-
tional response to epidermal growth factor stimulation, and identify the transforming growth factor-beta pathway
as a novel signalling pathway of interest that may regulate the expression of the Huntingtin (HTT) gene itself. The
dysregulation of HTT expression may contribute to the altered transcriptional phenotype observed in HD.








Huntington's Disease (HD) is an autosomal dominant neurodegen-
erative disorder caused by a CAG expansion within the ﬁrst exon of
the Huntingtin (HTT) gene, which gives rise to an expanded
polyglutamine tract in the huntingtin (HTT) protein. HD is characterised
by progressive motor abnormalities that manifest in the third to fourth
decades of life, and is also commonly associated with cognitive impair-
ments and psychiatric disturbances [1]. Neuronal dysfunction has been
found to occur prior to both striatal atrophy and overt motor symptom
onset [2,3]. It is therefore possible that cell death and degeneration in
HD-affected neuronal cells follow an initial period of dysregulation of
multiple cellular processes [4].
The regulation of kinase signalling is altered by, and in turn al-
ters, gene expression: in HD aberrant regulation of multiple kinase
signalling pathways has been shown [5]. The TGFβ pathway is a reg-
ulator of cell growth, proliferation and apoptosis, and is upstream ofAlzheimer's Disease, Friedman




. This is an open access article underthe core regulatory mothers against decapentaplegic-homolog
(SMAD) family of transcription factors [6,7]. To date, the character-
isation of TGFβ1 in association with HD has been limited, and has
yielded contradictory results; TGFβ1 is reduced in the peripheral
blood of asymptomatic HD patients, and is inversely correlated
with CAG repeat length [8]. However, while YAC128 and R6/2 mice
exhibit reduced TGFβ1 in the cortex, increased TGFβ1 has been ob-
served in HD patient and R6/2 mouse plasma [9]. Increased TGFβ
signalling has also been identiﬁed in the hippocampus of a transgen-
ic rat model of HD and in the R6/2 mouse model, where it has an in-
verse effect on neural stem cell proliferation [10], and in the cortex
of the Q175 mouse model [11]. The TGFβ pathway is upregulated
in human HD induced pluripotent stem cells (hiPSCs) and restored
to normal levels by replacement of the expanded CAG repeat with
a CAG repeat of non-pathogenic length [12]. Further analysis of
iPSC-derived neural progenitor cells (NPCs) carrying expanded
CAG repeats showed increased levels of TGFβ1 and enhanced
SMAD2 phosphorylation [11].
We investigated differential gene expression after epidermal growth
factor (EGF) stimulation in the immortalised StHdhQ111 cell model of HD
and identiﬁed TGFβ signalling as a dysregulated pathway. Further char-
acterisation of this pathway in both the StHdhQ111 model and in hiPSC-
derived NPCs revealed dysregulation of SMAD expression, localisation
and phosphorylation in cells carrying a CAG expansion, as well as evi-
dence of direct regulation of Htt gene expression by Smad3 activation.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.1. Cellular models
StHdhQ7/7, StHdhQ7/111 and StHdhQ111/111 immortalised embryonic
striatal cells were a kind gift from Marcy MacDonald (Molecular
Neurogenetics Unit, Massachusetts General Hospital, Massachusetts,
USA). Cell lines were grown and maintained in high glucose Dulbecco's
modiﬁed eaglemedium (DMEM; Life Technologies), containing 1% pen-
icillin-streptomycin solution, 1% 40 mg/ml Geneticin (both Life Tech-
nologies) and 10% fetal bovine serum (FBS; PAA), in a humid
environment at 33 °C with 5% CO2.
Q109 (heterozygous for a 109 CAG repeat expansion) and Q21
(wild-type, homozygous for 21 CAG repeats) hiPSC-derived lines were
maintained at the NPC stage of differentiation, in order to best match
the immortalised StHdhQ111 cell lines. NPCswere grown andmaintained
on Matrigel-coated plates (VWR) in Expansion media consisting of ad-
vanced DMEM F12, supplemented with 1% penicillin-streptomycin so-
lution, 1% glutamine supplement (all Life Technologies), 10 μg/ml
epidermal growth factor (EGF; Peprotech), 10 μg ﬁbroblast growth fac-
tor (FGF; Peprotech) and 2%Neurobrewwith vitamin A (Miltenyi). Cells
were grown in a humid environment at 37 °C with 5% CO2. Media was
replaced daily, and cells were passaged upon reaching 90% conﬂuence
using Accutase (Life Technologies). Immunoﬂuorescence was carried
out on these cells with common NPCmarkers to conﬁrm differentiation
stage (Supplementary Fig. 1).
2.2. Growth factor stimulation
Cellswere serumstarved overnight prior to treatmentwith EGF (Life
Technologies). Following serum starvation, cells were incubated for 2 h
with 100 ng/ml EGF, followed immediately by RNA extraction. Control
cells were serum starved for the same period of time and processed in
parallel with EGF treated cells.
In order to induce Smad phosphorylation, cells were serum
starved overnight, then incubated with 100 ng/ml of either mouse
(for StHdhQ111 cells) or human (for hiPSC-derived NPCs) TGFβ1
(NEB) for 30 min (for protein analysis) or for 2 h (for nucleic acid
analysis).
2.3. RNA extraction
RNA was extracted from cells grown in 6-well plates using the phe-
nol/chloroform method, precipitated in ethanol, and puriﬁed using
RNeasy MinElute Cleanup kit (Qiagen) according to manufacturer's
instructions.
2.4. Microarray and bioinformatics analysis
Themicroarraywas kindly carried out by Cardiff University's Central
Biotechnology Services (CBS), utilising the Affymetrix GeneChip Mouse
Gene 1.0 ST array system.
Raw microarray data was analysed in Partek® Genomics Suite™,
where it underwent quantile normalisation to log base 2 and median
polish probeset summarisation. There was no adjustment for GC con-
tent or probe sequence, and robust multi-array average (RMA) back-
ground correction was applied. Gene expression data were analysed
by a 2-way ANOVA containing a ‘genotype x EGF’ interaction term to
identify genes for which EGF stimulation resulted in signiﬁcantly differ-
ent expression changes between the genotypes, plus individual con-
trasts to identify simple main effects, that is, genes for which EGF
stimulation signiﬁcantly changes expression in a particular genotype.
The focus for the following stages of analysis was on the differences be-
tween StHdhQ7/7 and StHdhQ111/111 cell lines only, as this is where the
PCA suggested the largest differences are likely to lie. The following
lists of signiﬁcantly differentially expressed genes were created fromnormalised data with the parameters described in Supplementary
Table 1. Individual gene lists for differentially expressed genes following
EGF stimulation in StHdhQ7/7 and StHdhQ111/111 cells were created. As
there were a large number of signiﬁcant genes in the genoype x EGF in-
teraction list, only the top 500 most signiﬁcant genes were selected in
order to focus on the genes with the strongest effect. These lists were
put through pathway analyses using The Database for Annotation, Visu-
alization and Integrated Discovery (DAVID) v6.7 (http://david.abcc.
ncifcrf.gov/; [13,14]). To widen the analysis beyond the regulation of
transcription, all of the enriched functional terms from the DAVID anal-
ysis were subject to additional clustering to eliminate redundancy and
to clarify visualization.
Clustering of terms showing signiﬁcant enrichment from the
DAVID analysis was performed as follows: Firstly, the terms
were ranked in order of enrichment signiﬁcance, with the most
signiﬁcant term ﬁrst. For each term in turn, a measure of overlap
was calculated between that term and the terms in each of the
existing clusters. The measure of overlap used was the Jaccard
index, calculated as the number of genes associated with both
terms divided by the number of genes associated with either term.
The term was assigned to the cluster with which it had the highest
average Jaccard index, provided this was N50%. If the term did not
have an average Jaccard index N50% with any existing cluster, it
was placed in a new cluster. This process was repeated until the
end of the list of terms was reached. The resulting clusters were
visualised in Cytoscape [15].
2.5. qRTPCR
TaqMan (Life Technologies) qRTPCR technologies were utilised
throughout this project using a two-step protocol. Extracted RNA was
reverse transcribed to cDNA using the High Capacity RNA-to-cDNA kit
(Life Technologies) according to manufacturer's instructions, prior to
quantitative PCR utilising pre-designed TaqMan gene expression assays
and Fast Advanced Master Mix (Life Technologies) according to
manufacturer's instructions.
2.6. Western blotting
Protein lysates were extracted from StHdhQ111 and NPC lines using
10× Cell Lysis Buffer (NEB) according to manufacturer's instructions.
20 μg protein from each sample was resolved on a 4–12% Bis-Tris gel
(Life Technologies) and electroblotted onto a PVDF membrane
(Millipore). Blots were incubated for 30min in 5% skimmedmilk powder
in PBS with 0.1% Tween (PBS-T), and were then incubated overnight at
4 °C with the appropriate primary antibody. The next day, blots were
washed with PBS-T, and incubated with the appropriate peroxidase sec-
ondary antibody (Vector Laboratories) for 1 h at room temperature.
Bandswere thendetectedusing an enhanced chemiluminescentHRP sub-
strate (SuperSignalWest Dura ExtendedDuration Substrate; Fisher Scien-
tiﬁc), and visualised after exposure onto Hyperﬁlm (Fisher Scientiﬁc) and
processing through an Ecomax X-ray ﬁlm processor. Processed blots were
then stripped using Restore PLUS stripping buffer (Fisher Scientiﬁc),
probed with additional antibodies and re-imaged. Blots were stripped
and re-probed up to a maximum of 4 times before being discarded.
2.7. Immunoﬂuorescence
Cells were grown on glass coverslips and ﬁxed by incubation with
10% Formalin solution (Sigma Aldrich). They were then permeabilised
with 0.1% Triton x-100 (Life Technologies) in PBS, and blocked with
1% (w/v) bovine serum albumin (BSA; Sigma Aldrich) in PBS. Cells
were then incubated with the relevant primary antibody for 1 h in a
humid environment at 37 °C, followed by the appropriate AlexaFluor
secondary antibody (LifeTechnologies) for 1 h in a humid environment
at 37 °C, while wrapped in foil. Coverslips were mounted onto glass
Fig. 1. Functional annotation networks of differential gene expression following EGF stimulation. A. StHdhQ7/7 and StHdhQ111/111 DAVID functional annotations for differential gene
expression following EGF stimulation, following our clustering algorithm and visualised together as pathway networks in Cytoscape. Node colour saturation is indicative of StHdhQ7/7
cluster p-value, and the width of node outlines indicates StHdhQ111/111 cluster p-values (thicker outlines correspond to smaller p-values). Node size positively correlates with the size of
the gene set contributing to StHdhQ7/7-associated nodes. Edge width positively correlates with the similarity coefﬁcient between the two connected nodes. B. DAVID functional
annotations following our clustering algorithm for the interaction term gene list, visualised as pathway networks in Cytoscape. Node colour saturation is indicative of cluster p-value,
node size positively correlates with the size of the gene set contributing to the node. Edge width positively correlates with the similarity coefﬁcient between the two connected nodes.
3K.R. Bowles et al. / Cellular Signalling 31 (2017) 1–14microscope slides using ProLong Gold antifade reagent with DAPI (Life
Technologies), and stored in the dark at 4 °C for at least 24 h before vi-
sualization. Slides were imaged on a Leica DM6000B ﬂuorescent micro-
scope and nuclear/cytoplasmic mean pixel intensity ratios were
calculated as previously described [16]
2.8. Antibodies
See Supplementary Table 2.2.9. Chromatin immunoprecipitation
ChIP was carried out using approximately 4 × 107 cells per
condition, grown in multiple 15 cm dishes. Prior to chromatin
preparation, DNA was crosslinked using formaldehyde and
glycine. Chromatin preparation, digestion and immunoprecipita-
tion were carried out using the SimpleChIP kit (NEB), according
to manufacturer's instructions. The antibodies used for chromatin
immunoprecipitation were anti-SMAD3 (1:50; NEB) and anti-
Table 1
Clustered functional annotations for genes differentially expressed between baseline and following EGF stimulation. Signiﬁcant DAVID functional annotations following our clustering




p-value No. genes p-value No. genes
PIRSF001719:FOS TRANSFORMING PROTEIN 9.52 × 10−4 3
GO:0051789~RESPONSE TO PROTEIN STIMULUS 1.52 × 10−3 6
GO:0048589~DEVELOPMENTAL GROWTH 2.81 × 10−3 6
GO:0003002~REGIONALIZATION 2.28 × 10−4 10
DEVELOPMENTAL PROTEIN 3.47 × 10−3 16
GO:0006355~REGULATION OF TRANSCRIPTION, DNA-DEPENDENT 8.13 × 10−12 45 9.16 × 10−13 45
GO:0048514~BLOOD VESSEL MORPHOGENESIS 1.35 × 10−6 13
IPR013087:ZINC FINGER, C2H2-TYPE/INTEGRASE, DNA-BINDING 6.31 × 10−5 15
GO:0045859~REGULATION OF PROTEIN KINASE ACTIVITY 1.50 × 10−4 10
GO:0048729~TISSUE MORPHOGENESIS 2.13 × 10−4 11
GO:0051094~POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 4.65 × 10−4 10 2.28 × 10−4 10
MMU04010:MAPK SIGNALLING PATHWAY 4.88 × 10−4 11 5.26 × 10−5 11
GO:0044092~NEGATIVE REGULATION OF MOLECULAR FUNCTION 2.86 × 10−3 7
GO:0009611~RESPONSE TO WOUNDING 3.14 × 10−3 11
GO:0048511~RHYTHMIC PROCESS 3.71 × 10−3 6 3.47 × 10−4 7
B
Node p-value No. genes
PHOSPHOPROTEIN 8.01 × 10−14 228
GO:0042127~REGULATION OF CELL PROLIFERATION 1.08 × 10−11 44
TRANSCRIPTION REGULATION 5.48 × 10−10 75
GO:0048598~EMBRYONIC MORPHOGENESIS 2.43 × 10−8 30
GO:0040007~GROWTH 1.55 × 10−6 19
GO:0007507~HEART DEVELOPMENT 3.10 × 10−6 20
MMU04010:MAPK SIGNALLING PATHWAY 3.42 × 10−6 22
MMU04350:TGF-BETA SIGNALLING PATHWAY 1.21 × 10−5 12
GO:0045596~NEGATIVE REGULATION OF CELL DIFFERENTIATION 1.26 × 10−5 17
GO:0051789~RESPONSE TO PROTEIN STIMULUS 5.81 × 10−5 11
GO:0010941~REGULATION OF CELL DEATH 7.28 × 10−5 31
GO:0051094~POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 9.11 × 10−5 17
GO:0048608~REPRODUCTIVE STRUCTURE DEVELOPMENT 9.60 × 10−5 13
GO:0008201~HEPARIN BINDING 1.75 × 10−4 10
GO:0022405~HAIR CYCLE PROCESS 2.20 × 10−4 8
GO:0043583~EAR DEVELOPMENT 2.61 × 10−4 11
METAL-BINDING 3.03 × 10−4 96
MMU05210:COLORECTAL CANCER 3.35 × 10−4 10
GO:0007242~INTRACELLULAR SIGNALLING CASCADE 3.49 × 10−4 41
GROWTH FACTOR 6.52 × 10−4 11
GO:0007178~TRANSMEMBRANE RECEPTOR PROTEIN SERINE/THREONINE KINASE SIGNALLING PATHWAY 6.96 × 10−4 10
GO:0006928~CELL MOTION 8.90 × 10−4 21
DEVELOPMENTAL PROTEIN 9.92 × 10−4 34
GO:0009968~NEGATIVE REGULATION OF SIGNAL TRANSDUCTION 1.18 × 10−3 13
GO:0048145~REGULATION OF FIBROBLAST PROLIFERATION 1.33 × 10−3 5
GO:0001890~PLACENTA DEVELOPMENT 1.43 × 10−3 9
MMU05222:SMALL CELL LUNG CANCER 1.46 × 10−3 9
GO:0048008~PLATELET-DERIVED GROWTH FACTOR RECEPTOR SIGNALLING PATHWAY 2.29 × 10−3 5
GO:0030155~REGULATION OF CELL ADHESION 2.35 × 10−3 9
ALTERNATIVE SPLICING 2.63 × 10−3 130
GO:0017017~MAP KINASE TYROSINE/SERINE/THREONINE PHOSPHATASE ACTIVITY 2.64 × 10−3 4
CLEAVAGE ON PAIR OF BASIC RESIDUES 3.25 × 10−3 14
GO:0045165~CELL FATE COMMITMENT 3.72 × 10−3 11
GO:0008285~NEGATIVE REGULATION OF CELL PROLIFERATION 4.05 × 10−3 14
GO:0032869~CELLULAR RESPONSE TO INSULIN STIMULUS 4.10 × 10−3 6
GO:0001570~VASCULOGENESIS 4.10 × 10−3 6
CYCLIN 4.55 × 10−3 6
GO:0021915~NEURAL TUBE DEVELOPMENT 4.56 × 10−3 8
APOPTOSIS 4.66 × 10−3 17
GO:0051056~REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 4.71 × 10−3 14
GO:0045765~REGULATION OF ANGIOGENESIS 5.00 × 10−3 6
4 K.R. Bowles et al. / Cellular Signalling 31 (2017) 1–14phosphorylated SMAD3 (1:100; NEB). Histone H3 (1:50) and
normal rabbit IgG (1 μg) were used as negative controls (provided
in SimpleChIP kit). The resulting precipitated DNA was ampliﬁed
using qPCR and primers against the 5′ end of the Htt gene, incorpo-
rating the SBE region. Both antibodies were compared against
normal rabbit IgG. Puriﬁed DNA from the ChIP process was
quantiﬁed by Sybr Green (Life Technologies) qPCR using thefollowing conditions; a. initial denaturation 95 °C 3 min, b. dena-
turation 95 °C 15 s, c. anneal and extension 60 °C 60 s, d. repeat
b and c for a total of 40 cycles. qPCR primers were designed to
incorporate the Smad binding element (SBE) in the 5′ upstream
promoter region of the Htt gene, and were as follows; forward
5’CTGAGCGCCTTGGTTCCG-3′, reverse 5′- ATCAGCTTTTCCAGGG
TTGC-3′.
Table 2
Fold change gene expression between StHdhQ7/7 and StHdhQ111/111 cells for TGFβ pathway-related genes following microarray analysis.
Gene ID Gene name StHdhQ111/111 vs StHdhQ7/7 fold change p-value
Smurf2 Smad speciﬁc E3 ubiquitin protein ligase 2 1.74 2.1 × 10−13
Tgfβ1 Transforming growth factor beta 1 −1.5 2.4 × 10−14
Tgfβr1 TGF-β receptor 1 −1.2 1.6 × 10−5
Tgfβ2 Transforming growth factor beta 2 1.5 1.2 × 10−14
Tgfβr2 TGF-β receptor 2 3 5.2 × 10−33
Tgfβ3 Transforming growth factor beta 3 3 2.0 × 10−25
Tgfβr3 TGF-β receptor 3 6 2.1 × 10−27
Tgfβi TGF-β induced protein 11.4 2.1 × 10−30
Smad1 Mothers against decapentaplegic homolog 1 −1 4.5 × 10−1
Smad2 Mothers against decapentaplegic homolog 2 −1.2 7.8 × 10−9
Smad3 Mothers against decapentaplegic homolog 3 1.27 1.20 × 10−12
Smad4 Mothers against decapentaplegic homolog 4 −1.03537 3.9 × 10−2
Smad5 Mothers against decapentaplegic homolog 5 −1.16 1.7 × 10−9
Smad6 Mothers against decapentaplegic homolog 6 1.6 3.27 × 10−15
Smad7 Mothers against decapentaplegic homolog 7 −1.32277 1.69 × 10−9
5K.R. Bowles et al. / Cellular Signalling 31 (2017) 1–142.10. SMAD inhibition
In order to inhibit SMAD phosphorylation, cells were serum starved
overnight, and then incubated with 5uM of the SMAD2/3 inhibitorFig. 2. SMAD expression in mouse StHdh cell lines and human NPC cells. RQ values for Smad TF
prior to, and following 2 h stimulation with 100 ng/ml TGFβ1. * p b 0.05, ** p b 0.01, *** p b 0.0
differences within cell lines. N= 6 for each StHdhQ111 comparisons, and NSC comparisons. In
TGFβ1 (F1,30 = 4.814, p b 0.05) on the expression of Smad6, as well as a signiﬁcant genoty
TGFβ1 on SMAD6 expression in Q21 and Q109 cells (B; F1,17 = 7.548, p b 0.05), with the fold
in StHdhQ111 cells was increased by TGFβ1 stimulation (A; F1,30 = 59.295, p b 0.001), and
expression in Q21 and Q109 cells (B) also had a signiﬁcant effect of both genotype (F1,17 = 8SB525334 (Millipore) for 1 h prior to stimulation with 100 ng/ml
TGFβ1, and collection of either protein lysates or extraction of RNA.
Incubation with the equivalent volume of DMSO was used for control
conditions.expression in A. StHdhQ111 cell lines and B. hiPSC-derived NSCs measured by qRTPCR both
01. Asterisks denote a signiﬁcant difference between cell lines, hashes denote signiﬁcant
StHdhQ111 cells (A), there was an effect of both genotype (F2, 30 = 4.066, p b 0.05) and
pe x TGFβ1 interaction (F2,30 = 4.076, p b 0.05). There was also a signiﬁcant effect of
change increase being larger in Q109 cells (×1.8 Q21 vs. ×3.8 Q109). Smad7 expression
showed a signiﬁcant genotype x TGFβ1 interaction (F2,30 = 4.415, p b 0.05). SMAD7
.483, p b 0.05) and TGFβ1 (F1,17 = 14.927, p b 0.01).
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For qRTPCR analyses, delta-Ct values were subject to a 2-way
ANOVA, followed by post-hoc Tukey HSD tests. Western blots were
semi-quantitatively analysed using densitometry analysis in ImageJ.
The resulting measurements were normalised to measurements of α-
tubulin, and subject to the appropriate ANOVA and post-hoc Tukey
tests. ChIP qPCR data was analysed using the fold-enrichment method;
Ct values were normalised to the 2% input control, and the resulting
fold-change as compared to the IgG control was determined. The
resulting data was subject to a 2-way ANOVA and post-hoc Tukey tests.3. Results
3.1. Differential gene expression implicates TGFβ signalling pathways in
mutant HTT carrying cells
We detected substantial differences in gene expression between
StHdhQ7/7, StHdhQ7/111 and StHdhQ111/111 cell lines in response to EGF
treatment (Supplementary Fig. 2, Supplementary Table 3) with geno-
type being the main source of variation, and stimulation with EGF the
second largest source. There was also a mHTT/HTT gene dosage effect
on expression. As there were substantial differences in gene expression
proﬁles between StHdhQ7/7 and StHdhQ111/111 cells at baseline, we com-
pared the extent of gene expression changes following EGF treatment
within each cell line, rather than directly comparing levels of gene ex-
pression between the two genotypes.
Similar GO termswere implicated following EGF stimulation in both
StHdhQ7/7 and StHdhQ111/111 cell lines (Supplementary Table 4). Al-
though some pathways were associated with developmental processes,
themajority of themost signiﬁcant pathwayswere related to transcrip-
tion and transcriptional control. The Transcription and Positive Regula-
tion of Transcription pathways were also amongst the most signiﬁcant
pathways derived from genes showing differential effects of EGF stimu-
lation between cell lines.
We clustered our DAVID pathway analysis outputs to simplify path-
way enrichmentswithout compromising the diversity of terms by elim-
inating terms with overlapping genes (see Section 2, Methods).
Clustered nodeswere then visualised as a network of functional catego-
ries usingCytoscape (Fig. 1;(15)). The Regulation of Transcription, DNA-
dependent node contained the largest number of differentially
expressed genes in both genotypes and was signiﬁcantly enriched
(p= 8.13 × 1012). A comparison between StHdhQ7/7 and StHdhQ111/111
EGF-stimulated networks indicated minimal overlap between pathway
nodes for each genotype (Fig. 1), although Positive Regulation of Devel-
opmental Processes, Rhythmic Processes andMAPK Signallingwere sig-
niﬁcant for both cell lines (Table 1).
The same clustering was applied to a list of genes with a signiﬁcant
interaction between the effect of growth factor stimulation and geno-
type (Fig. 1; Table 1). At the centre of thenetwork is a large Phosphopro-
tein node consisting of 228 genes. The next two largest nodes are
Transcription Regulation and Alternative Splicing, which each share
66% of their gene set with the larger Phosphoprotein node. TGFβ Signal-
lingwas a signiﬁcantly enriched term resulting from the investigation of
differentially expressed genes between StHdhQ7/7 and StHdhQ111/111 cells
following EGF stimulation (Fig. 1; Table 1). Regulatory genes within this
pathway, such as Smad3 and Smad7, were also presentwithin the larger,
and more central Phosphoprotein node. We therefore followed this up
and investigated TGFβ signalling in HD cell models.Fig. 3. Total and phosphorylated Smad2 localisation inmouse StHdh cell lines. Fixed StHdhQ7/7, S
stained with antibodies against A. Smad2 and B. phosphorylated Smad2, with nuclei counters
20 μM. Figure representative of multiple images, N = 3. C. Quantiﬁcation of the nuclear/cyto
based on an average of 90 cells per condition, taken from 6 different frames across 3 experi
TGFβ, hashes indicate a signiﬁcant difference from StHdHQ7/7 cells. */# p b 0.05, **/## p b 0.01,3.2. Alterations in TGFβ signalling
One of the inhibitory members of the TGFβ signalling family, Smad6,
was identiﬁed and validated as a gene of interest (Supplementary Table
3). Both the activating Smad3 and inhibitory Smad7 exhibited similar
patterns of expression to the microarray data, as detected by qRTPCR,
and the effect of genotype on their expression at baseline was validated
(Supplementary Fig. 3).
Altered expression of additional members of the TGFβ signalling
pathway, such as Smads 1, 2, 5, and TGFβ receptors, was also observed
in StHdhQ111/111 cells within the microarray data, supporting the hy-
pothesis that this pathway is dysregulated in these cells (Table 2).
3.3. Characterisation of SMAD expression and activity in StHdhQ111 and
hiPS-derived neural progenitor cells
In order to characterise the TGFβ signalling pathway,we used TGFβ1
as a stimulus.
There was little effect of TGFβ1 stimulation on the expression of
Smads 1,2,4 and 5 inmouse StHdhQ111 cell lines or in the human iPSC-de-
rived NPCs, although multiple alterations in expression were seen be-
tween StHdhQ7/7, StHdhQ7/111 and StHdhQ111/111 cells both prior to, and
following TGFβ1 stimulation, which most commonly exhibited a trend
towards increased expression in mHtt-carrying cell lines (Fig. 2).
Smad3 expressionwas signiﬁcantly higher in StHdhQ111/111 cells at base-
line, compared with both StHdhQ7/7 (p b 0.001) and StHdhQ7/111 cells
(p b 0.05), whereas signiﬁcantly higher levels of SMAD3 expression
were observed in the human Q21 iPSC-derived NPCs compared to the
human Q109 iPSC-derived NPCs (p b 0.05). The expression of Smad6
and Smad7 were both altered by TGFβ1 stimulation in both mouse
StHdhQ111 and humanNPC lines (Fig. 2); therewas increased expression
of Smad6when homozygous Q111 alleles were present in the absence of
TGFβ1, and in StHdhQ7/111 cells in the presence of TGFβ1. Human Q21
and Q109 cells also exhibited increased SMAD6 expression in response
to TGFβ1. TGFβ1 stimulation increased Smad7 expression in all mouse
cell lines independent of genotype, and the most substantial effect of
TGFβ1 in the human iPSC lines was on SMAD7 expression. Despite the
Q109 NPC line being heterozygote for the mHTT expansion, the expres-
sion of SMAD7mirrors that observed in the homozygous StHdhQ111/111
line. Similar to the StHdhQ7/7 cells, there was a signiﬁcant effect of
TGFβ1 in control Q21 cells (p b 0.05), however this effect was sup-
pressed in Q109 cells, which expressed signiﬁcantly less SMAD7 com-
pared to Q21 cells following growth factor stimulation (p b 0.05).
3.4. Aberrant localisation of SMADproteins inmouse StHdhQ111 and human
NPC lines
The regulation of gene expression by SMAD transcription factors fol-
lowing activation of the TGFβ pathway involves cytoplasmic-nuclear
shuttling where activated phospho-SMAD/co-SMAD complexes form
transcriptional complexes and recruit DNA binding partners [7]. The
subcellular localisation of both total and phosphorylated Smads 2 and
3 were therefore assayed by immunoﬂuorescence. Typically, treatment
with TGFβ1 initiated increased nuclear localisation of total and phos-
phorylated Smads 2 and 3 in all cell lines (Figs. 3–5). However, the pres-
ence of mHTT appeared to alter the extent of the nuclear accumulation
of the Smads at both baseline, and following TGFβ1 stimulation.
There was little Smad2 accumulation in cell nuclei at baseline in
StHdhQ7/7 and Q21 cells (Figs. 3; 5), however following TGFβ1tHdhQ7/111 and StHdhQ111/111 cells stimulated with either 0 or 100 ng/ml TGFβ1 for 30 min,
tained with DAPI (blue). Images are representative of multiple replications. Scale bar =
plasmic mean pixel intensity (N/C MPI) ratio of the experiments presented in A and B,
ments (see Section 2, Methods). Asterisks denote a signiﬁcant difference from 0 ng/ml
***/### p b 0.001.
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9K.R. Bowles et al. / Cellular Signalling 31 (2017) 1–14stimulation its localizationwas almost exclusively nuclear, which is also
apparent in the nuclear/cytoplasmic (N/C) mean pixel intensity (MPI)
ratios calculated for these cells (Figs. 3C; 5C). Both StHdhQ7/111 and
StHdhQ111/111 cell lines had increased nuclear Smad2 at baseline com-
pared with StHdhQ7/7 cells. Although there was movement into cell nu-
clei following TGFβ1 stimulation, the accumulation of Smad2 was not
as exclusively nuclear as in StHdhQ7/7 cells, but remained in the area im-
mediately surrounding the nucleus (Fig. 3). In contrast, despite several
individual cells exhibiting high levels of nuclear SMAD2 in Q109 cells,
there was very little effect of TGFβ1 on overall SMAD2 subcellular
localisation. Phosphorylated Smad2 was primarily cytoplasmic at base-
line in StHdhQ7/7 and Q21 cells, although its nuclear presence increased
with mHtt gene dosage. There was movement of phosphorylated
Smad2 into the nucleus in all three StHdhQ111 lines and both NPC lines
following TGFβ1 stimulation (Figs. 3; 5).
At baseline, the localisation of Smad3was similar between StHdhQ7/7,
StHdhQ7/111 and StHdhQ111/111 cells (Fig. 4), but following TGFβ1 stimula-
tion, nuclear accumulation appeared higher in StHdhQ111/111 cells com-
pared to both StHdhQ7/111 and StHdhQ7/7 lines. Similarly, SMAD3
localisation was increasingly nuclear in Q21 and Q109 cells following
TGFβ1 stimulation (Fig. 5), although to a lesser extent in Q109 NPCs.
Nuclear over-accumulation of phosphorylated Smad3 was less ap-
parent in StHdhQ111/111 cells following TGFβ1 stimulation (Fig. 4), and
there was high variability between cells as some individual cells failed
to accumulate nuclear phosphorylated Smad3 to the same extent as
other cells in the same frame and as in StHdhQ7/7 cells (Fig. 4). In both
NPC lines, phosphorylated SMAD3was initiallymore nuclear at baseline
than total SMAD3, and while it increased in the nuclei of Q21 cells, this
effect was less clear in Q109 cells; although this again appeared to be
due to high variability between individual cells (Fig. 5).3.5. SMAD phosphorylation is inhibited in cell models of HD
SMAD protein expression and phosphorylation were determined in
mouse StHdh and human iPSC-derived NPC lines by western blot.
There was a reduction in total Smad2 detection in both StHdhQ7/7
(p b 0.01) and StHdhQ7/111 (p b 0.05) cells following TGFβ1 stimulation,
but no effect in the StHdhQ111/111 line (Fig. 6a); the reason for this reduc-
tion is unclear, although may be a result of induction of the ubiquitin-
proteasome system [17], or a technical artefact resulting from increased
Smad2 phosphorylation and therefore potentially reduced speciﬁcity of
the total Smad2 antibody. There was also no effect of genotype on the
level of total SMAD2 detected in the human NPCs (Fig. 6b). For all
three StHdh lines, there was a clear phosphorylation response in
Smad2 following a 30 min treatment with TGFβ1 (Fig. 6A), which was
similar in extent in both StHdhQ7/7 and StHdhQ7/111 cell lines (both
p b 0.001), but did not reach signiﬁcance in StHdhQ111/111 cells. As a
result, following TGFβ1 stimulation, the level of phosphorylated
Smad2 in StHdhQ111/111 cells was signiﬁcantly lower compared to both
StHdhQ7/7 (p b 0.05) and StHdhQ7/111 (p b 0.001) cells. The same pattern
is present in the phosphorylated/total Smad2 ratio in human cells (Fig.
6b). Similar to StHdh lines, SMAD2 did exhibit some phosphorylation
following TGFβ1 stimulation, although this response was not as pro-
nounced as in the immortalised mouse cell line. However, there was a
trend towards lower levels of phosphorylated SMAD2 in Q109 cells,
and a signiﬁcantly suppressed response following TGFβ1 stimulation
(p b 0.05). The same pattern of effect was also apparent in the phos-
phorylated/total SMAD2 ratio (Fig. 6b).
There was no apparent effect of either genotype or TGFβ1 stimulation
on the level of total Smad3 protein expression in either the mouse StHdhFig. 4. Total and phosphorylated Smad3 localisation inmouse StHdh cell lines. Fixed StHdhQ7/7, S
stainedwith antibodies against A. Smad3and B. phosphorylated Smad3,with nuclei counterstain
Figure representative of multiple images, N= 3. C. Quantiﬁcation of the nuclear/cytoplasmic m
average of 90 cells per condition, taken from 6 different frames across 3 experiments (see Sectio
a signiﬁcant difference from StHdHQ7/7 cells. */# p b 0.05, **/## p b 0.01, ***/### p b 0.001.cells or in the human NPC lines (Fig. 6). Similar to the effect on Smad2,
there was a substantial effect of TGFβ1 stimulation on the phosphoryla-
tion of all three cell lines (StHdhQ7/7 p b 0.01, StHdhQ7/111 p b 0.001,
StHdhQ111/111 p b 0.05; Fig. 6). However, there was only a modest phos-
phorylation response in the human NPC lines, and signiﬁcantly less
phosphorylated SMAD3 in Q109 cells at both baseline (p b 0.001) and
following TGFβ1 stimulation compared toQ21NPCs (Fig. 6). Calculation
of the phosphorylated/total Smad3 ratio demonstrates that there is a an
increased phosphorylation response in StHdhQ7/111 cells compared to
both StHdhQ7/7 (p b 0.01) and StHdhQ111/111 (p b 0.05) lines, and that
the same phosphorylation response is suppressed in StHdhQ111/111
cells (p b 0.05; Fig. 6. Similar to the StHdhQ111/111 cells, the level of phos-
phorylated SMAD3 in Q109 cells remains signiﬁcantly lower at both
baseline and following TGFβ1 stimulation compared to Q21 cells fol-
lowing calculation of the phosphorylated/total SMAD3 ratio (both
p b 0.001; Fig. 6).
3.6. SMAD3 associates with the HTT promoter
ASmadbinding element (SBE) consensus sequencewas identiﬁed in
the upstream promoter region of bothmouseHtt and human HTT (Sup-
plementary Fig. 4). Chromatin immunoprecipitation (ChIP) was there-
fore carried out in order to determine whether Smad TFs bind to the
Htt promoter in StHdhQ111 cells.
ChIPwas carried out using antibodies against both Smad3 and phos-
phorylated Smad3, as we observed a consistent dysregulation of its
phosphorylation and subcellular localisation in both StHdh and iPSC-de-
rived NPC lines. Htt promoter DNA was immunoprecipitated with the
total Smad3 antibody, but there were no differences between geno-
types (Fig. 7). However, the antibody against phosphorylated Smad3
pulled down substantial levels of Htt promoter sequence in both
baseline and TGFβ1 stimulated StHdhQ7/7 cells (Fig. 7). In StHdhQ7/111
and StHdhQ111/111 cell lines, signiﬁcantly less Htt DNA was
immunoprecipitated; in StHdhQ111/111 cells at baseline, the amount of
Htt detected in the precipitated DNA was signiﬁcantly higher than in
the IgG control, although not in StHdhQ7/111 cells. TGFβ1 stimulation
increased the level of immunoprecipitated Htt in StHdhQ7/111 and
StHdhQ111/111 cells (Fig. 7). We therefore examined whether HTT
expression was regulated by SMAD3 activation by using a speciﬁc
inhibitor of Smad 2 and 3 phosphorylation; SB525334.
Validation of the effects of SB525334 on Smad activationwas carried
out in both StHdh andNPC lines usingwestern blot and immunoﬂuores-
cence (Supplementary Figs. 5–8). There was a trend towards a TGFβ1-
induced increase inHtt expression in StHdhQ7/7 cells, whichwas blocked
by inhibition with SB525334 (Fig. 8). In contrast, while SB525334 inhi-
bition of Smads 2 and 3 reduced Htt expression in StHdhQ7/111 and
StHdhQ111/111 cells, the effect was less marked due to a lack of effect of
TGFβ1 alone.
The expression of HTT in Q21 and Q109 cells following SB525334
treatment was also determined by qRTPCR (Fig. 8). HTT expression
was consistently higher in Q21 compared with the Q109 cells and
TGFβ1 elicited a trend towards increased HTT expression in Q21 cells,
which was prevented by treatment with SB525334. There was no ob-
servable effect of SB525334 on the expression of HTT in Q109 cells, al-
though this is likely due to the absence of an initial effect of TGFβ1.
4. Discussion
By investigating differential gene expression between StHdhQ7/7 and
StHdhQ111/111 cell lines using microarray analysis, we identiﬁed TGFβtHdhQ7/111 and StHdhQ111/111 cells stimulated with either 0 or 100 ng/ml TGFβ1 for 30 min,
edwithDAPI (blue). Images are representative ofmultiple replications. Scale bar=20 μM.
ean pixel intensity (N/C MPI) ratio of the experiments presented in A and B, based on an
n 2,Methods). Asterisks denote a signiﬁcant difference from0 ng/ml TGFβ, hashes indicate
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Fig. 6.Western blot analysis of total and phosphorylated SMADs 2 and 3 in A. StHdhQ111 cell lines and B. NSCs, prior to, and following 30 min incubation with 100 ng/ml TGFβ1, and
representation of phosphorylated/total SMAD ratios from densitometry analysis of western blot images. All densitometry analyses of SMAD proteins are normalised to α-tubulin. *
p b 0.05, ** p b 0.01, *** p b 0.001. Images representative of multiple experiments. N= 5.
11K.R. Bowles et al. / Cellular Signalling 31 (2017) 1–14signalling as a signiﬁcantly altered signalling pathway, despite using
EGF as a stimulus. This is not surprising, as substantial crosstalk between
EGF and TGFβ pathways has previously been identiﬁed [18–21]; for ex-
ample, while SMAD7 is an inhibitor of SMAD signalling by competitive
interaction with the TGFβ type 1 receptor [22] and by interfering withFig. 5. Total and phosphorylated SMAD2 and SMAD3 localisation in human NPC lines. Fixed Q
antibodies against A. SMAD2 and phosphorylated SMAD2, and B. SMAD3 and phosphorylat
representative of multiple images. N = 3. C. Quantiﬁcation of the nuclear/cytoplasmic mea
average of 90 cells per condition, taken from 6 different frames across 3 experiments (see S
indicate a signiﬁcant difference from Q21 cells. */# p b 0.05, **/## p b 0.01, ***/### p b 0.001.SMAD-SMAD interactions [7], it is also responsive to EGF stimulation
in order to act as a negative regulator of this pathway [23]. Another sig-
niﬁcantly differentially expressed gene identiﬁed from our microarray
analysis, Spry2, is also known to mediate the crosstalk between these
two pathways; its activation is increased by stimulation of the EGF21 and Q109 iPSCs stimulated with either 0 or 100 ng/ml TGFβ for 30 min, stained with
ed SMAD3, and nuclei counterstained with DAPI (blue). Scale bar = 20 μM. Figures are
n pixel intensity (N/C MPI) ratio of the experiments presented in A and B, based on an
ection 2, Methods). Asterisks denote a signiﬁcant difference from 0 ng/ml TGFβ, hashes
Fig. 7.qPCRdata demonstrating the enrichment ofHttDNA fromChIP usingA. Smad3 andB. phosphorylated Smad3 antibodies, analysedusing the fold-enrichmentmethod (see Section 2,
Methods). Asterisks denote a signiﬁcant difference in precipitated Htt using either total or phosphorylated Smad3 antibodies compared to the IgG control. * p b 0.05, ** p b 0.01, ***
p b 0.001. N= 3.
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radation of the EGFR. TGFβ suppresses the transcription of Spry2,
degrading its protein and suppressing EGFR activation [24]. Enhance-
ment of the TGFβ signalling pathway would therefore be consistent
with a suppressed response to EGF, which we observe in StHdhQ111/111
cells both in these microarray data, and in our previously published
work [16].
The genes that were identiﬁed as having a stronger transcriptional
response in StHdhQ111/111 cells encode a diverse range of functions,
predominantly cellular survival and proliferation. However, the majori-
ty of genes on these lists are known to be responsive to TGFβ1 stimula-
tion, and several have direct associations with SMAD transcription
factors (TFs). For example, the HMGA2 protein regulates a feed forward
mechanism of gene transcription via a direct interaction with SMADs 3
and 4 [25]. Irf2bp2 encodes a muscle enriched TF [26] that has
been found to be a TGFβ responsive gene [27], as are Cdc42ep3 and
Gadd45g [28–30].
Our identiﬁcation of TGFβ signalling as a signiﬁcantly altered path-
way in a cell model of HD is consistent with a recent RNA-seq analysis
of HD patient iPSC-derived NPCs, where TGFβ signalling was one of
the most signiﬁcantly dysregulated pathways [11], and targets of
SMAD3 were over-represented within genes differentially expressed
between HD-NPCs and their isogenic controls [11].
In order to further characterise the TGFβ signalling pathway, we fo-
cused on the regulation of SMAD TFs in themouse StHdhQ111model and
in human iPSC-derived NPCs. The most consistent observation was for
suppressed expression of the inhibitory SMAD, SMAD7, in response to
TGFβ1 stimulation in StHdhQ111/111 and in Q109 NPCs, which would beFig. 8. HTT expression following SMAD inhibition. RQ values from qRTPCR for the expression
SB525334. There was a signiﬁcant effect of genotype on HTT expression in StHdhQ111 cells (A; Fsuggestive of reduced inhibition of TGFβ signalling. However, as the re-
maining expression data and protein characterisation data do not indi-
cate a substantial increase in TGFβ signalling activity, the lack of
SMAD7 responsiveness may be a compensatory mechanism in these
cells attempting to enhance kinase signalling and mediate transcrip-
tional regulation.
Immunoﬂuorescence analysis of StHdhQ7/7 cells and Q21 NPCs dem-
onstrates that stimulation with TGFβ1 is activating SMAD TFs by induc-
ing phosphorylation of SMADs 2 and 3 and their nuclear localisation,
which is required for SMAD-regulated transcriptional activity. This
translocation is altered in cells containing a CAG expansion. In particu-
lar, Smad2 exhibits increased nuclear localisation in StHdhQ7/111 and
StHdhQ111/111 cells, and phosphorylated SMAD2 is predominantly nucle-
ar in Q109 NPCs prior to TGFβ1 stimulation. This is consistent with the
increased SMAD2 phosphorylation identiﬁed in other HD patient-de-
rived NPCs [11]. Altered localisation and phosphorylation of SMAD3 is
also observed in both cell lines, although it is more consistent with a
generalised dysregulation and disordered response to TGFβ1, than nu-
clear accumulation in particular. As we do not observe an augmented
phosphorylation response in CAG-repeat expansion cell lines in re-
sponse to TGFβ1 bywesternblot, it is possible that the increased nuclear
localisation of these factors, combined with suppressed SMAD7 expres-
sion and inhibition,may be a compensatorymechanism to retain higher
TGFβ pathway activity in an otherwise detrimental environment.
An attempt to increase TGFβ signalling may be indicative of a
protective response in these cells; increasing TGFβ1 in cellular
growth media was found to reduce the activity of caspases 3 and 7
[11], and increased expression of TGFβ1 has been associated withof HTT in A. StHdhQ111 cells and B. NPCs following TGFβ1 stimulation and inhibition with
8,38 = 2.56, p b 0.05) and in NPCs (B; F1, 25 = 22.9333, p b 0.001). N= 6.
13K.R. Bowles et al. / Cellular Signalling 31 (2017) 1–14neuroprotection, astrogliosis and alleviation of neuroinﬂammation [31,
32], whereas its knockdown promoted neuronal loss in rats following
traumatic brain injury [32]. However, as microglia and astrocytes both
express TGFβ1 and are inextricably involved in these neuroprotective
processes [31–34], the culture of neuronal-like cells in isolation from
these other neural cell types will not be fully sufﬁcient for the elucida-
tion of the potential neuroprotective effects of increased TGFβ1 in
models of HD.
In addition to characterising the altered regulation of SMAD TFs in
StHdhQ111 cells and iPSC-derived NPCs, we demonstrate that a SMAD
binding element is present within the HTT promoter region, and
SMAD3 can bind directly to theHtt promoter in StHdhQ111 cells, suggest-
ing that SMAD3 activitymay directly regulate the expression ofHtt. This
was supported by the increased expression ofHTT in both StHdhQ7/7 and
Q21 cells following TGFβ1 stimulation, and the suppression of this effect
when SMAD activation was inhibited with the compound SB525334.
The increased expression of HTT following TGFβ1 stimulation was
not present in cells with an expanded CAG repeat, which is consistent
with the reduced afﬁnity of phosphorylated SMAD3 for the Htt
promoter in StHdhQ7/111 and StHdhQ111/111 cells. As TGFβ is required for
neurogenesis [35], as well as for midbrain dopaminergic neuronal de-
velopment [36], and HTT has also been implicated in the regulation of
neurogenesis [37,38] and is essential for embryonic development [39],
it is possible that TGFβ signallingmay be directly regulatingHTT expres-
sion in order for these processes to occur.
5. Conclusions
• We implicate dysregulation of the TGFβ signalling pathway in mouse
and human cell models of HD, consistent with recent RNA-seq data
from hiPSC-derived NPCs [11].
• Characterisation of the downstream SMADs within this pathway un-
covered widespread dysregulation, which may indicate a compensa-
tory, neuroprotective response to the CAG expansion.
• Finally, we demonstrate that SMAD3 binds to the HTT promoter, and
that HTT expression can be regulated by SMAD3 activation in the ab-
sence of the CAG expansion.
• This may have implications for neurogenesis and striatal develop-
ment. TGFβ signalling is therefore a possible target for diseasemodiﬁ-
cation and could prove to be a useful biomarker for disease
progression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cellsig.2016.12.005.
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